The aims of the present study were: (1) to compare the CHMP2B immunopositivity of the hippocampal GVDs in several neurodegenerative disorders that can present with pathological lesions containing phosphorylated tau protein; and (2) to investigate the association of CHMP2B-positive GVDs with tau pathology, to determine whether CHMP2B-positive GVDs and phosphorylated tau coexist among non-AD neurodegenerative disorders. The gene discussed is MAPT; the disease is Alzheimer disease.